RB1CC1 and lung carcinoma: Approximately 48.97% (95/194) LUAD and 47.4% (73/154) LUSC specimens displayed RB1CC1 nuclear subcellular localisation (Figure 7G), suggesting a large portion of lung cancer may benefit from ferroptosis‐based therapy.